Guest: Susan Feeney, DNP, FNP-BC, NP-CMusic Credit: Richard Onorato
This episode will review current literature on COVID-19 data.
Guest: Alan Ehrlich MD, FAAFP Music Credit: Richard Onorato
Antibiotics are frequently prescribed for upper respiratory infections, even when they are likely due to viral etiologies, or will resolve just as quickly without antibiotics. Many clinicians believe convincing patients they do not need to take an antibiotic is time consuming and frustrating for both parties. In fact, patients are often receptive to information on appropriate use, and the conversation can be done efficiently with practice.
Adults between the ages of 18 through 64 with immunocompromising conditions due to either anatomic defects or impaired immune response are at the highest risk for invasive pneumococcal disease. They need two different pneumococcal vaccines: pneumococcal conjugate vaccine (PCV13) at the time the risk factor is recognized and pneumococcal polysaccharide vaccine (PPSV23) at least 8 weeks later. This podcast will discuss how to identify these patients at high risk for pneumococcal disease and implement guidelines for administration of pneumococcal vaccination in this population. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/18/2020 and they are subject to change as new information is published.
The Advisory Committee on Immunization Practices (ACIP) makes shared clinical decision-making recommendations when individuals may benefit from vaccination, but broad vaccination of all people in that group is unlikely to have population-level impact. Such a recommendation is applicable to pneumococcal vaccines whereby pneumococcal conjugate vaccine (PCV13) is recommended for all adults 65 and older, while the administration of pneumococcal conjugate vaccine (PCV13) is based on shared decision-making. In this podcast, we will discuss the ACIP recommendations and the use of shared decision-making as it applies to pneumococcal vaccines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/18/2020 and they are subject to change as new information is published.
Because cell-mediated immunity declines with age, individuals aged 50 years and older are at increased risk for the reactivation of the latent varicella zoster virus that causes shingles. Learn about vaccination recommendations to prevent shingles and complications of herpes zoster, especially postherpetic neuralgia. Answer questions about shingles prevention and win at Jeopardy!
Join us for the first COVID-19 Pulse session of 2021! In the twenty-fourth episode of Pri-Med’s web series on COVID-19, faculty will walk through the Advisory Committee on Immunization Practices (ACIP) guidelines for COVID-19 vaccine prioritization as well as the newest data on these vaccines. This session will discuss the emerging SARS-CoV-2 variants and their potential implications. Faculty will conclude with a Q&A session to answer your most pressing COVID-19 questions. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 12/15/2020 and they are subject to change as new information is published.
These troubling times require communication among specialists and primary care. In this COVID-19 panel, primary care, and infectious disease faculty will team up to discuss the most pressing and frequently asked questions about this disease and its complications.
This presentation will highlight recent developments and controversies in the pediatrics field by utilizing case-based discussions, and reviewing current evidence-based guidelines. Among the topics discussed, emphasis will be placed on the appropriate selection of antibiotics for common skin and soft tissue infections in the era of bacterial resistance. Additionally, this session will include a review of the impact that COVID-19 has had in the pediatric population, and the potential hesitancy that providers will encounter once a pediatric COVID-19 vaccine becomes available.
Featuring Peter J. Hotez, MD, PhD
Globally, we are seeing a mixed picture of vaccinating the United States and the world against COVID-19, with tremendous progress containing the B.1.1.7 variant in the United States but failing to control widespread transmission in Africa and Latin America. Dr. Hotez will discuss the progress made to date with the US vaccination program, what we can expect toward the end of 2021 and into 2022, and how we can advance vaccinations globally. This session will also explore the impact of a rising and shifting anti-vaccine movement.
In this presentation on Lyme and other tickborne diseases, Dr. Solomon will review the clinical approach to patients with suspected tickborne disease. He will focus on a comprehensive review of Lyme disease including the clinical manifestations, the challenges and pitfalls in diagnostic testing, prevention of Lyme through the use of post-exposure prophylaxis, and the potential co-infections carried by the same vector. He will review the evidence on management of Post-Treatment Lyme Disease Syndrome and offer a rational approach to treatment. Finally, he will discuss the social controversy around “Chronic Lyme.”